Amylyx Pharmaceuticals

Senior Director, Health Economics and Outcome Research/Real World Evidence

Cambridge, Massachusetts, United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

About Amylyx Pharmaceuticals

Amylyx is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, with an audacious mission to develop novel therapies for high unmet needs. We are currently focused on post-bariatric hypoglycemia (PBH), Wolfram syndrome, progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS). Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve.

Our mission is powered by our people. Our core values – be audacious, be curious, be authentic, be engaged, and be accountable – create a culture of caring. Amylyx has assembled an experienced team ready to take action because the communities we serve have no time to wait. If you share our passion and determination, we encourage you to read the opportunity below and apply.

THE OPPORTUNITY

The Senior Director, Health Economics and Outcomes Research (HEOR)/Real World Evidence (RWE) at Amylyx Pharmaceuticals will report to the SVP of Medical Affairs. This position will be an expert and experienced leader, engaging cross functionally to develop and drive HEOR and evidence generation strategies. The Senior Director will play an integral role in developing and communicating the value proposition for Amylyx’ assets, including our lead program in post-bariatric hypoglycemia (PBH). This role will drive development of strategies, methods, and tools to ensure successful market access, adoption, and long-term impact in support of Amylyx’ mission to find solutions for patients with high unmet needs.

RESPONSIBILITIES

Strategic Leadership

  • Build and lead the HEOR function including the development of integrated HEOR and evidence generation strategies and tactical plans to support Amylyx’s therapeutic programs
  • Lead evidence gap analyses that will inform the HEOR strategic and tactical plans and lead cross-functional data generation and communication planning efforts to support health economic/value proposition and inform understanding of treatment patterns, disease burden, patient-reported outcomes, and unmet needs

Evidence Generation & Study Execution

  • Design and execute projects, such as burden of illness, real-world clinical outcomes, clinical registries, retrospective database analyses, and meta-analyses.
  • Provide scientific support for protocol development, target product profiles, data collection strategies, literature review and evidence synthesis

Stakeholder Engagement & Communication

  • Oversee the development of peer-reviewed publications, conference presentations, and internal communication of HEOR findings.
  • Support global market access strategy and plans for Amylyx pipeline products including, identifying opportunities for early scientific advice with key health technology assessment (HTA) agencies, regulatory support and preparing for global HTA models. Incorporate any recommendations into the clinical development program.

Cross-Functional Collaboration

  • Ensure all HEOR tactics are aligned cross-functionally with business strategies and regulatory guidelines.
  • Monitor and interpret U.S. policy changes (e.g., IRA, CMS guidance) and translate implications into actionable HEOR strategies.
  • Collaborate with Market Access and Medical Affairs to develop and maintain evidence packages tailored to U.S. payers, including commercial plans, Medicare, and Medicaid.

Team & Vendor Management

  • Lead vendor selection and manage external research partners to ensure high-quality and timely study delivery.
  • Build and manage a team to support innovative real-world evidence generation and health economics research.
  • Manage HEOR budget planning and resource allocation to ensure efficient execution of strategic priorities

REQUIRED QUALIFICATIONS

  • 10+ years healthcare or pharmaceutical industry experience with minimum 7 in HEOR
  • Master's Degree (MS, MPH, PharmD, PhD) in a relevant discipline (e.g., health economics, medicine, pharmacy, public health, epidemiology) required

Skills

Health Economics and Outcomes Research (HEOR)
Real World Evidence (RWE)
Evidence Generation Strategies
Value Proposition Development
Market Access
Strategic Planning
Data Generation
Communication Planning

Amylyx Pharmaceuticals

Develops treatments for neurodegenerative diseases

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Cambridge, MassachusettsHeadquarters
2013Year Founded
$166.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Remote Work Options

Risks

Relyvrio's Phase III failure raises concerns about ALS treatment efficacy.
Low stock offering price suggests potential financial instability.
New CCO may disrupt commercialization strategies if not aligned with goals.

Differentiation

Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.
AMX0035 is a promising drug for ALS and Alzheimer's treatment.
Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Upsides

Positive Phase II results for AMX0035 in ALS boost its potential.
Partnership with Gubra accelerates drug development for neurodegenerative diseases.
Regulatory support for rare diseases aids Amylyx's Wolfram syndrome efforts.

Land your dream remote job 3x faster with AI